Evidence map›Paper›PMID 36148777›Full record

ReviewBioscience reports2022

Combatting antimicrobial resistance via the cysteine biosynthesis pathway in bacterial pathogens.

Joanna L Hicks, Keely E A Oldham, Jack McGarvie, Emma J Walker

Open access · goldAbstract readReview
In one paragraph

Review in Bioscience reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Serine Acetyltransferase fromInternational journal of molecular sciences · 2026
    Article
  3. Review
  4. Article
  5. Article
  6. iScience · 2026
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Alkyl gallates inhibit serineFrontiers in microbiology · 2023
    Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Joanna L HicksTe Huataki Waiora, School of Health, University of Waikato, Hamilton, New Zealand.ORCID 0000-0002-0307-0923
Keely E A OldhamTe Huataki Waiora, School of Health, University of Waikato, Hamilton, New Zealand.
Jack McGarvieTe Huataki Waiora, School of Health, University of Waikato, Hamilton, New Zealand.
Emma J WalkerTe Huataki Waiora, School of Health, University of Waikato, Hamilton, New Zealand.
University of Waikato · NZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antibiotics are the cornerstone of modern medicine and agriculture, and rising antibiotic resistance is one the biggest threats to global health and food security. Identifying new and different druggable targets for the development of new antibiotics is absolutely crucial to overcome resistance. Adjuvant strategies that either enhance the activity of existing antibiotics or improve clearance by the host immune system provide another mechanism to combat antibiotic resistance. Targeting a combination of essential and non-essential enzymes that play key roles in bacterial metabolism is a promising strategy to develop new antimicrobials and adjuvants, respectively. The enzymatic synthesis of L-cysteine is one such strategy. Cysteine plays a key role in proteins and is crucial for the synthesis of many biomolecules important for defense against the host immune system. Cysteine synthesis is a two-step process, catalyzed by two enzymes. Serine acetyltransferase (CysE) catalyzes the first step to synthesize the pathway intermediate O-acetylserine, and O-acetylserine sulfhydrylase (CysK/CysM) catalyzes the second step using sulfide or thiosulfate to produce cysteine. Disruption of the cysteine biosynthesis pathway results in dysregulated sulfur metabolism, altering the redox state of the cell leading to decreased fitness, enhanced susceptibility to oxidative stress and increased sensitivity to antibiotics. In this review, we summarize the structure and mechanism of characterized CysE and CysK/CysM enzymes from a variety of bacterial pathogens, and the evidence that support targeting these enzymes for the development of new antimicrobials or antibiotic adjuvants. In addition, we explore and compare compounds identified thus far that target these enzymes.

Indexed as

Cysteine SynthaseSerine O-AcetyltransferaseAnti-Bacterial AgentsBacteriaCysteineDrug Resistance, BacterialSulfidesSulfurThiosulfatesAnti-Bacterial AgentsCysteineCysteine SynthaseSerine O-AcetyltransferaseSulfidesSulfurThiosulfatesCysECysKCysMcysteine synthesisO-acetylserine sulfhydrylaseserine acetyltransferase

Identifiers

PMID36148777
PMCPMC9547175
OpenAlexW4296801439

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.